Dr Reddy’s Bollaram Facility Receives USFDA Form 483 with 7 Observations

21 Nov 2024 , 11:14 PM

Dr Reddy’s Laboratories announced the successful completion of a GMP inspection by the USFDA at its API manufacturing facility (CTO-2) in Bollaram, Hyderabad.

The inspection was carried out between November 13 and November 19, 2024. Following the inspection, the USFDA issued a Form 483 containing seven observations. Dr Reddy’s has committed to addressing the identified observations within the prescribed timeline. The company aims to ensure compliance with all regulatory requirements to maintain its operational standards.

In the National Stock Exchange, shares of Dr Reddy’s Laboratories closed at ₹1192.80 which is a 1.70% dip than the previous close. Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.